NCT03672240View on ClinicalTrials.gov

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 30, 2018

Primary Completion Date

October 30, 2019

Study Completion Date

June 30, 2020

Conditions
Non-Muscle Invasive Bladder Cancer (NMIBC)
Interventions
DRUG

APL-1202

To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin

Trial Locations (2)

10029

The Icahn School of Medicine at Mt. Sinai, New York

29572

Carolina Urologic Research Center, Myrtle Beach

Sponsors
All Listed Sponsors
lead

Asieris Pharmaceutical Technologies Co., Ltd.

INDUSTRY